The purpose of this study is to compare the clinical efficacy of the buprenorphine/naloxone
combination tablet to methadone for opioid maintenance treatment.
S/A brief "Summary for the Public"
Individuals must be at least 18 years of age, currently opioid dependent and meet FDA
criteria for narcotic maintenance treatment. Co-morbid substance abuse or dependence
disorders may also be present. Individuals must be healthy despite drug dependency.
Individuals with evidence of an active Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness,
organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular
disease) or pregnant female subjects are excluded from study participation.